Etigilimab

• CAT Number: I040366
• CAS Number: 2044984-83-8
• Purity: ≥95%

Etigilimab(CAT: I040366) is a humanized IgG1 monoclonal antibody that targets TIGIT (T cell immunoreceptor with Ig and ITIM domains), an immune checkpoint receptor expressed on T cells and natural killer (NK) cells. By blocking TIGIT, Etigilimab enhances immune cell activation and restores anti-tumor immune responses, offering a novel mechanism for cancer immunotherapy. It is currently under clinical investigation for the treatment of advanced solid tumors, both as monotherapy and in combination with other immune checkpoint inhibitors like anti-PD-1/PD-L1 agents. Etigilimab is a promising candidate in the immuno-oncology field, aimed at overcoming tumor-induced immune suppression and enhancing durable clinical responses.